Rock Creek Pharmaceuticals Reports on Inhibition of STAT 3 Activation, A Key Marker of Inflammation, In Phase I Clinical Trial in Europe
Brixton Metals Announces Upsize of Previously Announced Non-Brokered Private Placement to $8 Million and Closing of Second Tranche
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026